Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2006-02-21
2006-02-21
Guzo, David (Department: 1636)
Chemistry: molecular biology and microbiology
Vector, per se
C536S023100, C536S023700, C536S023720, C514S615000, C514S818000, C514S04400A
Reexamination Certificate
active
07001759
ABSTRACT:
Methods of introducing genetic material into cells of an individual and compositions and kits for practicing the same are disclosed. The methods comprise the steps of contacting cells of an individual with a polynucleotide function enhancer and administering to the cells, a nucleic acid molecule that is free of retroviral particles. The nucleic acid molecule comprises a nucleotide sequence that encodes a protein that comprises at least one epitope that is identical or substantially similar to an epitope of a pathogen antigen or an antigen associated with a hyperproliferative or autoimmune disease, a protein otherwise missing from the individual due to a missing, non-functional, or partially functioning gene, or a protein that produces a therapeutic effect on an individual. Methods of prophylactically and therapeutically immunizing an individual against pathogens are disclosed. Pharmaceutical compositions and kits for practicing methods of the present invention are disclosed.
REFERENCES:
patent: 3688765 (1972-09-01), Gasaway
patent: 4224404 (1980-09-01), Viza et al.
patent: 4394448 (1983-07-01), Szoka, Jr. et al.
patent: 4596556 (1986-06-01), Morrow et al.
patent: 4680027 (1987-07-01), Parsons et al.
patent: 4806463 (1989-02-01), Goodchild et al.
patent: 4945050 (1990-07-01), Sanford et al.
patent: 5017487 (1991-05-01), Stunnenberg et al.
patent: 5024656 (1991-06-01), Gasaway et al.
patent: 5036006 (1991-07-01), Sanford et al.
patent: 5185254 (1993-02-01), Linnenbach
patent: 5466676 (1995-11-01), Booth et al.
patent: 5593972 (1997-01-01), Weiner et al.
patent: 6214804 (2001-04-01), Felgner et al.
patent: 0 386 882 (1990-09-01), None
patent: WO 90/11092 (1990-10-01), None
patent: WO 9011092 (1990-10-01), None
patent: WO 91/07425 (1991-05-01), None
patent: WO 91/09958 (1991-07-01), None
patent: WO 91/12329 (1991-08-01), None
patent: WO 92/20316 (1992-11-01), None
patent: WO 93/17706 (1993-09-01), None
patent: WO 93/23552 (1993-11-01), None
Webster et al. DNA vaccines A review of developments. Biodrugs vol. 8(4):273-292, Oct. 1997.
Rabinovich et al. Vaccine technologies: View to the future. Science vol. 265:1401-1404, Sep. 1994.
Cho et al. Macromolecular versus small-molecule therapeutics: Drug discovery,development and clinical considerations. TIBTECH vol. 14:153-158, May 1996.
Piscitelli et al., Immune-based therapies for treatmetn of HIV infection. Ann. Pharmacol. vol. 30:62-76, Feb. 1996.
Danko et al. Pharmacological enhancement of in vivo foreign gene expression in muscle. Gene Therapy, vol. 1(2):114-121, Feb. 1994.
Chattergoon et al. Genetic immunization: a new era in vaccines and immune therapeutics. FASEB J. vol. 11:753-563, Jun. 1997.
Weiner et al. Genetic vaccines. Scientific American. vol. 281(1):34-42, Jul. 1999.
Yasutomi et al. A vaccine-elicited, single viral epitope-specific cytotoxic T lymphocyte response does not pretect against intravenous, cell-free simian immunodeficiency virus challenge. J. Virol. vol. 69(4):2279-2284, 1995.
Price et al. Lineage analysis in teh vertebrate nervous system by retrovirus-mediated gene transfer. PNAS vol. 84:156-16, 1987.
E. T. Juengst, BMJ, 2003, vol. 326, pp. 1410-1411.
A. Mountain, TIBTECH, 2000, vol. 18, pp. 119-128.
E. B. Kmiec, American Scientist, 1999, vol. 87, pp. 240-247.
Verma et al., Nature, 1997, vol. 329, pp. 239-242.
W. French Anderson, Nature, 1998, vol. 392, pp. 25-30.
Barnett et al.,Conf. Adv. AIDS Vaccine Dev., Feb. 11-15, 1996, p. 126, Poster 6.
Bruck et al., “HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees,”Vaccine, 1994, 12(12), 1141-1148.
Girard et al., “Failure of a Human Immunodeficiency Virus Type 1 (HIV-1) Subtype B-Derived Vaccine to Prevent Infection of Chimpanzees by an HIV-1 Subtype E Strain,”J. Viol., 1996, 70(11), 8229-8233.
Orkin et al.,Report and Recommendations of the Panel to Assess the NIH-Investment in Research on Gene Therapy, Dec. 7, 1995.
Reitz, M.S., “Letter to the Editor on the Historical Origins of HIV-1 (MN) and (RF)”,AIDS Research and Human Retroviruses, 1992, 8, 1539-1541.
Thomason, D.B. et al., “Stable incorporation of a bacterial gene into adult rat skeletal muscle in vivo”,Am. J. Physiology, 1990, 258(3), C578-C581.
Zolla-Pazner et al.,Int. Conf. AIDS(Canada), Jul. 7-12, 1996, 11(1), p. 14, Abstract No. Mo.A.406.
Chaudhary et al., “A Rapid Method of Cloning Functional Variable-Region Antibody Genes inEscherichia colias Single-Chain Immunotoxins”,PNAS USA, 1990, 87, 1066-1070.
Chen, L. et al., “Human Papillomavirus Type 16 Nucleoprotein E7 is a Tumor Rejection Antigen”,PNAS USA, 1991, 88, 110-114.
Estin, C.D. et al., “Transfected Mouse Melanoma Lines that Express Vairous Levels of Human Melanoma-Associated Antigen p97”,J. Nat. Can. Institute, 1989, 81(6), 445-448.
Fendly, B.M. et al., “The Extracellular Domain of HER2
eu is a Potential Immunogen for Active Specific Immunotherapy of Breast Cancer”,J. Biological Response Modifiers, 1990, 9, 449-455.
Fidler, I. et al., “Biological and Experimental Consequences of the Zonal Composition of Solid Tumors”,Cancer Research, 1981, 41, 3266-3267.
Fisher et al., “A Molecular Clone of HTLV-III with Biological Activity”,Nature, 1985, 316, 262-265.
Haynes, B.F., “Scientific and Social Issues of Human Immunodeficiency Virus Vaccine Development”,Science, 1993, 260, 1279-1286.
Hoffenbach, A. et al., “Unusually High Frequencies of HIV-Specific Cytotoxic T Lymphocytes in Humans”,J. Immunology, 1989, 142, 452-462.
Howell et al., “Limited T-Cell receptor Beta-Chain heterogeneity Among Interleukin 2 Receptor-Positive Synovial T Cells Suggests a Role for Superantigen in Rheumatoir Arthritis”,PNAS USA, 1988, 88, 10921-10925.
Kabat et al., “Sequence of Proteins of Immunological Interest”, U.S. Dept. of Health and Human Services, bethesda, MD, 1987.
Khoka, R. et al., “Suppression of Invasion by Inducible Expression of Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) in B16-F10 Melanoma Cells”,J. National Cancer Institute, 1992, 84(13), 1017-1022.
Kundig et al., “Nonimmunogenic Tumor Cells May Efficiently Restimulate Tumor Antigen-Specific Cytotoxic T Cells”,J. Immunology, 1993, 150, 4450-4456.
Ledley, F., “Clinical Considerations in the Design of Protocols for Somatic Gene Therapy”,Human Gene Therapy, 1991, 2, 77-83.
McCoy, Bargmann and Weinberg, “Human Colon Carcinoma Kiras2 Oncogene and its Corresponding Proto-Oncogene”,Mol. Cell Biol., 1984, 4, 1577-1582.
Oksenberg et al., “Limited Heterogeneity of Rearranged T-Cell receptor V Alpha Transcripts in Brains of Multiple Sclerosis Patients”,Nature, 1990, 345, 344-348.
Paliard et al., “Evidence for the Effects of a Superantigen in Rheumatoid Arthritis”,Science, 1991, 253, 325-329.
Reddel, R.R. et al., “Neoplastic Transformation of Human Mesothelial Cells Transfected with a Mutant c-Ha-ras Oncogene”,Proceedings of the 80th Annual Meeting of the American Association for Cancer Research, May 24-27, 1989, 30, Abs. 1743.
Torpey III, D. et al., “Effects of Adoptive Immunotherapy with Autologous CD8+T Lymphocytes on Immunologic Parameters: Lymphocyte Subsets and Cytotoxic Activity”,Clinical Immunology and Immunopathology, 1993, 68(3), 263-272.
Warner, J.F. et al., “Induction of HIV-Specific CTL and Antibody Responses in Mice Using Retroviral Vector-Transduced Cells”,AIDS Res. and Human Retroviruses, 1991, 7, 645-655.
Williams et al., “Restricted Heterogeneity of T Cell Receptor Transcripts in Rheumatoid Synovium”,J. Clin. Invest., 1992, 90, 326-333.
Wucherpfennig et al., “Shared Human T Cell receptor V Beta Usage to Immunodominant Regions of Myelin Basic Protein”,Science, 1990, 248, 1016-1019.
Brandsma et al., “Use of a Rapid, Efficient Inoculation Method to Induce Papillomas by Cottontail Rabbit Papillomavi
Wang Bin
Weiner David B.
Williams William V.
Cozen O'Connor P.C.
Guzo David
The Trustees of the University of Pennsylvania
The Wistar Institute
LandOfFree
Compositions and methods for delivery of genetic material does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for delivery of genetic material, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for delivery of genetic material will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3636472